Corporate Round Funded Biotechnology Startups
The 12 most recent corporate rounds in biotechnology shown here span July 2021 through October 2022, with Freenome's $290M raise in South San Francisco sta…
The 12 most recent corporate rounds in biotechnology shown here span July 2021 through October 2022, with Freenome's $290M raise in South San Francisco standing out as the largest disclosed figure by a substantial margin. The remaining disclosed rounds are considerably smaller — Nabsys (Providence, Rhode Island) closed $25M in April 2022, CytoReason (Tel Aviv) raised $20M in September 2022, and Tavros Therapeutics (Durham, North Carolina) brought in $18M the following month.
Four of the 12 rounds carried undisclosed amounts, including SyntheX, Ionpath, and Tegmine Therapeutics — all with California addresses. California accounts for five of the twelve companies overall, spanning San Francisco, South San Francisco, Menlo Park, and Huntington Beach. The remaining entries extend to Providence, Boston, Durham, and four international markets: Israel, India, Germany, and the United Kingdom, underscoring the global footprint of corporate strategic investment in the biotechnology sector.
Most recent rounds
12 shownRelated listings
Frequently asked
What was the largest disclosed corporate round among these biotechs?
Freenome, based in South San Francisco, raised $290M in January 2022 — the largest disclosed figure in this set by a wide margin. The next largest are Nabsys at $25M (Providence, April 2022) and CytoReason at $20M (Tel Aviv, September 2022).
How many of these rounds have a disclosed funding amount?
Eight of the 12 rounds list a specific figure; four — SyntheX, Newlight Technologies, Ionpath, and Tegmine Therapeutics — are undisclosed. Among the disclosed amounts, the range runs from Active Motif's $100K to Freenome's $290M, with five entries clustering between $14M and $25M.
Which cities and regions appear most frequently in this segment?
California accounts for five of the 12 companies: SyntheX and Tegmine Therapeutics in San Francisco, Freenome in South San Francisco, Ionpath in Menlo Park, and Newlight Technologies in Huntington Beach. Outside California, U.S. representation includes Durham, Providence, and Boston.
Are there non-U.S. biotechs in this group?
Four of the 12 companies are headquartered outside the United States: CytoReason in Tel Aviv, Yapan Bio in Hyderabad, Active Motif in Tegernheim (Germany), and MiNA Therapeutics in London — indicating that corporate strategic rounds in biotechnology cross geographies well beyond U.S. hubs.
What date range do these corporate rounds cover?
The rounds span from MiNA Therapeutics' close in July 2021 to Tavros Therapeutics' raise in October 2022, a window of roughly 15 months. Activity is distributed across that span, with no single quarter dominating the count.
How small can a biotechnology corporate round get in this data?
Active Motif in Tegernheim, Germany closed a $100K corporate round in September 2021, and Alloplex Biotherapeutics in Boston raised $1M in August 2021 — both well below the $14M–$25M band where most other disclosed rounds sit, illustrating that corporate round structures are used at a wide range of check sizes.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.